Related Experiment Video
Updated: Feb 6, 2026
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy
Michael Phan1,2, Margaret F Watson2,3, Tommy Alain2,3
1Center for Innovative Cancer Research , Ottawa Hospital Research Institute , 501 Smyth Road , Ottawa , Ontario K1H 8L6 , Canada.
Abstract:
Over the past 20 years there has been a dramatic expansion in the testing of oncolytic viruses (OVs) for the treatment of cancer. OVs are unique biotherapeutics that induce multimodal responses toward tumors, from direct cytopathic effects on cancer cells, to tumor associated blood vessel disruption, and ultimately potent stimulation of anti-tumor immune activation. These agents are highly targeted and can be efficacious as cancer treatments resulting in some patients experiencing complete tumor regression and even cures from OV monotherapy. However, most patients have limited responses with viral replication in tumors often found to be modest and transient. To augment OV replication, increase bystander killing of cancer cells, and/or stimulate stronger targeted anti-cancer immune responses, drug combination approaches have taken center stage for translation to the clinic. Here we comprehensively review drugs that have been combined with OVs to increase therapeutic efficacy, examining the proposed mechanisms of action, and we discuss trends in pharmaco-viral immunotherapeutic approaches currently being investigated.
Insights
Oncolytic viruses (OVs) show promise for cancer treatment, but combinations with other drugs are needed to improve efficacy and immune response for better patient outcomes.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Oncolytic viruses (OVs) are biotherapeutics that target cancer cells through direct killing, vascular disruption, and immune stimulation.
- While OVs can lead to complete tumor regression in some patients, limited viral replication and transient responses necessitate combination strategies.
Purpose of the Study:
- To review drugs combined with OVs to enhance therapeutic efficacy.
- To examine the mechanisms of action for these drug combinations.
- To discuss current trends in pharmaco-viral immunotherapeutic approaches.
Main Methods:
- Comprehensive literature review of studies combining oncolytic viruses with other drugs.
- Analysis of proposed mechanisms of action for combined therapies.
- Identification and discussion of emerging trends in pharmaco-viral immunotherapy.
Main Results:
- Drug combinations aim to augment OV replication, increase bystander killing, and enhance anti-tumor immune responses.
- Various drug classes are being investigated in combination with OVs.
- Pharmaco-viral immunotherapy represents a growing area of clinical investigation.
Conclusions:
- Combination therapy is crucial for overcoming limitations of OV monotherapy.
- Strategic drug combinations can potentiate the efficacy of oncolytic viruses.
- Further research into pharmaco-viral immunotherapeutics holds significant potential for advancing cancer treatment.
Related Concept Videos
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
01:29Therapeutic Drug Monitoring: Affecting Factors
01:16Therapeutic Drug Monitoring: Overview and Classification
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
00:50What are Viruses?